Neutral endopeptidase and angiotensin-converting enzyme - key enzymes terminating the action of neuroendocrine mediators

被引:43
|
作者
Scholzen, TE [1 ]
Luger, TA [1 ]
机构
[1] Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany
关键词
allergic contact dermatitis; angiotensin-converting enzyme; neuroimmunology; neutral endopeptidase; skin;
D O I
10.1111/j.1600-0625.2004.00260.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Zinc-metalloproteases, such as neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), effectively control the bioavailability of peptide mediators released from sensory nerves, immune and skin cells during the cutaneous response to endogenous or exogenous noxious stimuli. Functional inactivation of NEP or ACE by transient inhibition or permanent genomic deletion results in a relative abundance of substance P (SP) and bradykinin (BK); this augments murine allergic contact dermatitis (ACD) by affecting ACD sensitization and elicitation, which involves neurokinin 1 receptors (NK1), BK receptors (B-2) and an intact cutaneous sensory nervous system. Present evidence suggests that increased SP via NK1 is capable of boosting important functions of SP- and NK1-expressing dendritic cells (DCs) and T cells (TCs) in an auto- or paracrine manner, which promotes ACD antigen sensitization. Moreover, skin inflammation or wounding in vivo, as well as treatment of epidermal and dermal cells by UV light and inflammatory mediators in vitro, regulates NEP and ACE expression and activity. Likewise, NEP and ACE are capable of processing neuroendocrine hormones, such as adrenocorticotropin and alpha-melanocyte-stimulating hormone. Thus, present data indicate that ACE and NEP, via proteolytic cleavage of peptide mediators and growth factors, represent important control factors for the inflammatory response in skin disorders such as psoriasis or allergic inflammation, but may also be capable of affecting pigmentation, cell survival, wound healing and tissue regeneration.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 50 条
  • [41] 4-SUBSTITUTED PROLINE DERIVATIVES THAT INHIBIT ANGIOTENSIN-CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE-24.11
    BHAGWAT, SS
    FINK, CA
    GUDE, C
    CHAN, K
    QIAO, Y
    SAKANE, Y
    BERRY, C
    GHAI, RD
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (22) : 2673 - 2676
  • [42] DIASTEREOSELECTIVE SYNTHESIS OF MIXANPRIL, AN ORALLY-ACTIVE DUAL INHIBITOR OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN-CONVERTING ENZYME
    TURCAUD, S
    GONZALEZ, W
    MICHEL, JB
    ROQUES, BP
    FOURNIEZALUSKI, MC
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (17) : 1893 - 1898
  • [43] Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11
    Chatelain, RE
    Ghai, RD
    Trapani, AJ
    Odorico, LM
    Dardik, BN
    De Lombaert, S
    Lappe, RW
    Fink, CA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 284 (03): : 974 - 982
  • [44] COMBINED INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN-CONVERTING ENZYME IN CARDIOMYOPATHIC HAMSTERS WITH COMPENSATED HEART-FAILURE
    TRIPPODO, NC
    FOX, M
    NATARAJAN, V
    PANCHAL, BC
    DORSO, CR
    ASAAD, MM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1993, 267 (01): : 108 - 116
  • [45] The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240
    Cirillo, I
    Martin, NE
    Brennan, B
    Barrett, JS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (12): : 1379 - 1384
  • [46] Inhibition of cardiac and renal angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) by omapatrilat in normotensive rats
    Bäcklund, T
    Palojoki, E
    Grönholm, T
    Vuolteenaho, O
    Laine, M
    Tikkanen, I
    EUROPEAN HEART JOURNAL, 2000, 21 : 58 - 58
  • [47] CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme
    Battistini, Bruno
    Daull, Philippe
    Jeng, Arco Y.
    CARDIOVASCULAR DRUG REVIEWS, 2005, 23 (04): : 317 - 330
  • [48] Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes
    Tikkanen, I
    Tikkanen, T
    Cao, ZM
    Allen, TJ
    Davis, BJ
    Lassila, M
    Casley, D
    Johnston, CI
    Burrell, LM
    Cooper, ME
    JOURNAL OF HYPERTENSION, 2002, 20 (04) : 707 - 714
  • [49] ANTIHYPERTENSIVE ACTIVITY DURING INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN CONVERTING ENZYME
    SEYMOUR, AA
    SWERDEL, JN
    ABBOAOFFEI, B
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (03) : 456 - 465
  • [50] DUAL INHIBITOR OF ANGIOTENSIN-I-CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE
    DAGE, RC
    MEHDI, S
    GIROUX, EL
    FRENCH, JF
    FLYNN, GA
    CIRCULATION, 1992, 86 (04) : 140 - 140